HemoglobinopathiesNCT06831799
ERN-EuroBloodNet Registry on Patients With Rare Red Blood Cell Defects and COVID-19
An observational study of Hemoglobinopathies and Sickle Cell Disease, run by Hospital Universitari Vall d'Hebron Research Institute at 1 site in Spain.
Trial summary
Patients with red blood cell disorders (RBCDs), such as Sickle cell disease (SCD) and Thalassemia, are chronic, life-threatening conditions that can become multi-organ complications over time, and are likely at an increased risk of COVID-19-related complications. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Anemia
- What is being tested?
- Non applicable, is a patient registry
- How many people
- 684 participants
- Where
- 1 siteSpain
- Study dates
- 15 Apr 2020to 31 Dec 2023
- How long will I take part?
- 1 Month
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Patients both pediatric and adults with confirmed COVID19 and affected by a rare anaemia disorder due to a red blood cell defect according to the following ORPHA codes for rare diseases: * 68364 Hemoglobinopathy * 275752 Sickle Cell Disease and related diseases * 848 Beta-thalassemia * 846 Alpha-Thalassaemia * 98363 Rare hemolytic anemia * 98369 Rare constitutional hemolytic anemia due to an enzyme disorder * 98364 Rare constitutional hemolytic anemia due to a red cell membrane anomaly
Who may be able to join
- Patients both pediatric and adults with confirmed COVID-19 and affected by a rare anaemia disorder due to a red blood cell defect
Who cannot join
None listed.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: ERN-EuroBloodNet European Collaborative Platform to Share COVID-19 Data in Patients With Red Blood Cell Disorders in Real Time
Patients with red blood cell disorders (RBCDs), such as Sickle cell disease (SCD) and Thalassemia, are chronic, life-threatening conditions that can become multi-organ complications over time, and are likely at an increased risk of COVID-19-related complications. Patients at the highest risk include the elderly (>50 in our population), those with a history of respiratory or cardiac disease and those with other comorbidities. Several patients affected by RBCDs undergo splenectomy as therapeutic option to improve their level of hemoglobin concentration. Splenectomized patients, or in the case of SCD with functional hyposplenism, are more vulnerable to bacterial infections / superinfections after viral infection. Acute pulmonary syndrome (ACS) is the main cause of morbidity in SCD in middle-high income countries, and is often triggered by infectious events. Currently, there is no literature on the subject. Thus, any recommendation available comes from the experience gained with previous Coronaviruses infections. Accordingly, the correct treatment and management of infection by Coronavirus SARS-COV-2 (COVID-19) in patients affected by RBCDs may be challenging given the rapid spread of the pandemic and limited literature so far, especially in some countries. Accordingly, there is an urgent need to pool evidence in a unique repository on patients affected by RBCDs and COVID-19 in order to reach critical numbers to facilitate the medical decision making process across Europe.
The Registry on patients with rare RBCDs and COVID-19 is an initiative conceived in the core of the European Reference Network on Rare Hematological Diseases (ERN-EuroBloodNet, FPA 739541, www.eurobloodnet.eu) aiming at supporting medical practice of COVID-19 in these patients by gathering evidence on pediatric and adult COVID-19 confirmed cases in RBCDs across Europe.
Read the detailed description
The Registry on patients with rare red blood cell disorders (RBCDs) and COVID-19 is an initiative conceived in the core of the European Reference Network on Rare Hematological Diseases (ERN-EuroBloodNet, FPA 739541, www.eurobloodnet.eu) aiming at supporting medical practice of COVID-19 in these patients by gathering evidence on pediatric and adult COVID-19 confirmed cases in RBCDs across Europe.
Primary objective of the registry is to pool evidence on the clinical management and outcomes of patients affected by red blood cell disorders and COVID-19 for supporting daily medical practice while enabling inter-professional consultation of complex cases. Secondary objective includes the performance of observational studies in the different cohorts of patients, including Sickle Cell Disease, Thalassaemia, Enzymopathies and Membranopathies patients in pediatric and or adult stages.
The network of hospitals that will be created from this registry will hold regular meetings to analyze the data that are being introduced and to discuss possible measures against COVID-19 based on them. The collaboration will continue with the development of observational studies that will give the necessary evidence to make recommendations for COVID-19 management in hematological patients.
METHODOLOGY
Inclusion criteria include both pediatric and adults patients with confirmed COVID-19 and affected by a rare anaemia disorder due to a red blood cell defect. Data set elements include:
- Demographics: country of living, sex, age (only year of birth)
- Data related to Red blood cell disorder: diagnosis, co-morbidities, treatments, splenectomy, blood transfusion requirement.
- Data related to COVID-19: date and method for diagnosis, severity grade, clinical manifestations i.e. pneumonia, symptoms days, acute events, treatments, days of hospitalization, days at intensive care unit, sequela, death.
The registry has been developed by Vall d'Hebron Research Institute using Redcap, a secure web application for building and managing online databases. Individual patients' data will be gathered in a codified way.
ETHICS AND GDPR COMPLIANCE
The processing of personal data is conducted fully respecting the Regulation (EU) 2016/679 (General Data Protection Regulation), including legal basis and special requirements and safeguards to ensure the safety and the confidentiality of the data subjects.
The Research Ethics Committee of the Vall d'Hebron's Hospital has confirmed that this exceptional case justifies the waiver of informed consent.
PROCESSING OF THE DATA
The patient's information included in the database is pseudonymised by single codification. The minimization principle of data protection is followed (i.e. only year of age is collected, no identified data is collected, and only clinical data of the health care is collected). The medical doctors at each center have a coding table in which the code can be linked to the patient's personal information. This table is safely guarded by the medical doctor and never leaves the center. All the information stored in the database is pseudonymised.
- Conditions
- Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Anemia, Sickle Beta Thalassemia, Sickle-Cell; Hemoglobinopathy, Sickle Cell Hemoglobin C
- Being tested
- Non applicable, is a patient registry
- Keywords
- COVID-19, Hemoglobinopathy, Sickle cell disease, Sickle Cell Anemia, Sickle cell-beta-thalassemia, Sickle cell-hemoglobin, Beta-Thalassemia, Beta Thalassemia Major, Beta Thalassemia Intermedia, Delta-Beta Thalassaemia, Alpha-Thalassemia, Hemoglobin, Rare hemolytic anemia, Hereditary Spherocytosis, Hereditary Elliptocytosis, Hereditary Stomatocytosis
- Medical subject headings
- Hemoglobinopathies, Anemia, Sickle Cell, Hemoglobin SC Disease, beta-Thalassemia, Beta Thalassemia, Dominant Inclusion Body Type, Delta-Beta Thalassemia, alpha-Thalassemia, Anemia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Non applicable, is a patient registryOther
Non applicable, is a patient registry
| Study group | Role | What they receive |
|---|---|---|
| Pediatric Sickle cell disease patients infected by COVID-19 | Sickle cell diagnosed patients (<18 years old) infected by COVID-19 Receives: Other: Non applicable, is a patient registry | |
| Adult Sickle cell disease patients infected by COVID-19 | Sickle cell diagnosed patients (≥18 years old) infected by COVID-19 Receives: Other: Non applicable, is a patient registry | |
| Pediatric Thalassemia patients infected by COVID-19 | Thalassemia-diagnosed patients (<18 years old) infected by COVID-19 Receives: Other: Non applicable, is a patient registry | |
| Adult Thalassemia patients infected by COVID-19 | Thalassemia-diagnosed patients (≥18 years old) infected by COVID-19 Receives: Other: Non applicable, is a patient registry | |
| Pediatric Enzymopathy patients infected by COVID-19 | Enzymopathy-diagnosed patients (<18 years old) infected by COVID-19 Receives: Other: Non applicable, is a patient registry | |
| Adult Enzymopathy patients infected by COVID-19 | Enzymopathy-diagnosed patients (≥18 years old) infected by COVID-19 Receives: Other: Non applicable, is a patient registry | |
| Pediatric Membranopathy patients infected by COVID-19 | Membranopathy-diagnosed patients (<18 years old) infected by COVID-19 Receives: Other: Non applicable, is a patient registry | |
| Adult Membranopathy patients infected by COVID-19 | Membranopathy-diagnosed patients (<18 years old) infected by COVID-19 Receives: Other: Non applicable, is a patient registry |
What is being measured
The primary outcome is the main question the study is designed to answer.
Clinical Management and Outcomes in Patients with Red Blood Cell Disorders and COVID-19
- COVID-19 clinical manifestations and required treatment in each cohort (Sickle Cell Disease, Thalassemia, Enzymopathies, and Membranopathies)..
Measured: Through study completion, an average of 3 years
Secondary outcomes (1)
Secondary Analysis in Different Cohorts of Patients with Red Blood Cell Disorders and COVID-19:
- Descriptive analysis of demographic and baseline disease characteristics in each cohort (Sickle Cell Disease, Thalassemia, Enzymopathies, and Membranopathies).
- COVID-19 clínical manifestations in each cohort.
- Identification of preventive measures and risk factors related to severe COVID-19 in each cohort
Measured: Through study completion, an average of 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Feb 2025
- Study start15 Apr 2020
- Primary completion30 Jun 2023
- Study completion31 Dec 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HemoglobinopathiesStudies of the same condition, open and under way.
- More trials run by Hospital Universitari Vall d'Hebron Research InstituteThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Other
- Enrolment
- 684 participants (actual)
- Target duration
- 1 Month
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Collaborators
- European Georges Pompidou Hospital, Hospital General Universitario Gregorio Marañon, Hospital Vall d'Hebron, Unidade Local de Saúde de Coimbra, EPE, University Hospital Freiburg, Azienda Ospedaliera di Padova, Hôpital Necker-Enfants Malades, Guy's and St Thomas' NHS Foundation Trust, Erasme University Hospital, Aghia Sophia Children's Hospital of Athens, Cyprus Institute of Neurology and Genetics, University Hospital Heidelberg, Children's Health Ireland, San Luigi Gonzaga Hospital, Oxford University Hospitals NHS Trust, UMC Utrecht, General Hospital of Athens Elpis, Amsterdam UMC, Brno University Hospital, Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello, University Hospital, Gentofte, Copenhagen, Institute of Hematology and Blood Transfusion, Czech Republic, Universitaire Ziekenhuizen KU Leuven, Palacky University
- Responsible party
- Sponsor
- Investigators
- María del Mar Mañú Pereira, PhD, Principal investigator, Vall d'Hebron Institut de Recerca, Barcelona (Spain) and ERN-EuroBloodNetPablo Velasco Puyó, MD, Principal investigator, Vall d'Hebron University Hospital, Barcelona (Spain)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06831799
- Sponsor's protocol ID
- VHI-ERN-2020-00
- Other IDs
- PR(AG)215/2020
- Status last verified
- Feb 2025
- First submitted
- 17 Feb 2023
- Last updated
- 18 Feb 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Feb 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- ERN-EuroBloodNet European Collaborative Platform to Share COVID-19 Data in Patients With Red Blood Cell Disorders in Real Time
- ClinicalTrials.gov ID
- NCT06831799
- Acronym / sponsor ID
- VHI-ERN-2020-00
- Conditions
- Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Anemia, Sickle Beta Thalassemia, Sickle-Cell; Hemoglobinopathy, Sickle Cell Hemoglobin C
- Keywords
- COVID-19, Hemoglobinopathy, Sickle cell disease, Sickle Cell Anemia, Sickle cell-beta-thalassemia, Sickle cell-hemoglobin, Beta-Thalassemia, Beta Thalassemia Major
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 684 participants (actual)
- Lead sponsor
- Hospital Universitari Vall d'Hebron Research InstituteUniversity, hospital or other
- Collaborators
- European Georges Pompidou Hospital, Hospital General Universitario Gregorio Marañon, Hospital Vall d'Hebron, Unidade Local de Saúde de Coimbra, EPE, University Hospital Freiburg, Azienda Ospedaliera di Padova, Hôpital Necker-Enfants Malades, Guy's and St Thomas' NHS Foundation Trust, Erasme University Hospital, Aghia Sophia Children's Hospital of Athens, Cyprus Institute of Neurology and Genetics, University Hospital Heidelberg, Children's Health Ireland, San Luigi Gonzaga Hospital, Oxford University Hospitals NHS Trust, UMC Utrecht, General Hospital of Athens Elpis, Amsterdam UMC, Brno University Hospital, Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello, University Hospital, Gentofte, Copenhagen, Institute of Hematology and Blood Transfusion, Czech Republic, Universitaire Ziekenhuizen KU Leuven, Palacky University
- Study start
- 15 Apr 2020 (actual)
- Primary completion
- 30 Jun 2023 (actual)
- Study completion
- 31 Dec 2023 (actual)
- First posted
- 18 Feb 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Patients with red blood cell disorders (RBCDs), such as Sickle cell disease (SCD) and Thalassemia, are chronic, life-threatening conditions that can become multi-organ complications over time, and are likely at an increased risk of COVID-19-related complications. Patients at the highest risk include the elderly (>50 in our population), those with a history of respiratory or cardiac disease and those with other comorbidities. Several patients affected by RBCDs undergo splenectomy as therapeutic option to improve their level of hemoglobin concentration. Splenectomized patients, or in the case of SCD with functional hyposplenism, are more vulnerable to bacterial infections / superinfections after viral infection. Acute pulmonary syndrome (ACS) is the main cause of morbidity in SCD in middle-high income countries, and is often triggered by infectious events. Currently, there is no literature on the subject. Thus, any recommendation available comes from the experience gained with previous Coronaviruses infections. Accordingly, the correct treatment and management of infection by Coronavirus SARS-COV-2 (COVID-19) in patients affected by RBCDs may be challenging given the rapid spread of the pandemic and limited literature so far, especially in some countries. Accordingly, there is an urgent need to pool evidence in a unique repository on patients affected by RBCDs and COVID-19 in order to reach critical numbers to facilitate the medical decision making process across Europe.
The Registry on patients with rare RBCDs and COVID-19 is an initiative conceived in the core of the European Reference Network on Rare Hematological Diseases (ERN-EuroBloodNet, FPA 739541, www.eurobloodnet.eu) aiming at supporting medical practice of COVID-19 in these patients by gathering evidence on pediatric and adult COVID-19 confirmed cases in RBCDs across Europe.
Detailed description
The Registry on patients with rare red blood cell disorders (RBCDs) and COVID-19 is an initiative conceived in the core of the European Reference Network on Rare Hematological Diseases (ERN-EuroBloodNet, FPA 739541, www.eurobloodnet.eu) aiming at supporting medical practice of COVID-19 in these patients by gathering evidence on pediatric and adult COVID-19 confirmed cases in RBCDs across Europe.
Primary objective of the registry is to pool evidence on the clinical management and outcomes of patients affected by red blood cell disorders and COVID-19 for supporting daily medical practice while enabling inter-professional consultation of complex cases. Secondary objective includes the performance of observational studies in the different cohorts of patients, including Sickle Cell Disease, Thalassaemia, Enzymopathies and Membranopathies patients in pediatric and or adult stages.
The network of hospitals that will be created from this registry will hold regular meetings to analyze the data that are being introduced and to discuss possible measures against COVID-19 based on them. The collaboration will continue with the development of observational studies that will give the necessary evidence to make recommendations for COVID-19 management in hematological patients.
METHODOLOGY
Inclusion criteria include both pediatric and adults patients with confirmed COVID-19 and affected by a rare anaemia disorder due to a red blood cell defect. Data set elements include:
- Demographics: country of living, sex, age (only year of birth)
- Data related to Red blood cell disorder: diagnosis, co-morbidities, treatments, splenectomy, blood transfusion requirement.
- Data related to COVID-19: date and method for diagnosis, severity grade, clinical manifestations i.e. pneumonia, symptoms days, acute events, treatments, days of hospitalization, days at intensive care unit, sequela, death.
The registry has been developed by Vall d'Hebron Research Institute using Redcap, a secure web application for building and managing online databases. Individual patients' data will be gathered in a codified way.
ETHICS AND GDPR COMPLIANCE
The processing of personal data is conducted fully respecting the Regulation (EU) 2016/679 (General Data Protection Regulation), including legal basis and special requirements and safeguards to ensure the safety and the confidentiality of the data subjects.
The Research Ethics Committee of the Vall d'Hebron's Hospital has confirmed that this exceptional case justifies the waiver of informed consent.
PROCESSING OF THE DATA
The patient's information included in the database is pseudonymised by single codification. The minimization principle of data protection is followed (i.e. only year of age is collected, no identified data is collected, and only clinical data of the health care is collected). The medical doctors at each center have a coding table in which the code can be linked to the patient's personal information. This table is safely guarded by the medical doctor and never leaves the center. All the information stored in the database is pseudonymised.
Study design
- Observational model
- Case-control
- Time perspective
- Other
- Target follow-up
- 1 Month
- Number of arms
- 8
| Arm | Type | Receives |
|---|---|---|
| Pediatric Sickle cell disease patients infected by COVID-19 | – | Other: Non applicable, is a patient registrySickle cell diagnosed patients (<18 years old) infected by COVID-19 |
| Adult Sickle cell disease patients infected by COVID-19 | – | Other: Non applicable, is a patient registrySickle cell diagnosed patients (≥18 years old) infected by COVID-19 |
| Pediatric Thalassemia patients infected by COVID-19 | – | Other: Non applicable, is a patient registryThalassemia-diagnosed patients (<18 years old) infected by COVID-19 |
| Adult Thalassemia patients infected by COVID-19 | – | Other: Non applicable, is a patient registryThalassemia-diagnosed patients (≥18 years old) infected by COVID-19 |
| Pediatric Enzymopathy patients infected by COVID-19 | – | Other: Non applicable, is a patient registryEnzymopathy-diagnosed patients (<18 years old) infected by COVID-19 |
| Adult Enzymopathy patients infected by COVID-19 | – | Other: Non applicable, is a patient registryEnzymopathy-diagnosed patients (≥18 years old) infected by COVID-19 |
| Pediatric Membranopathy patients infected by COVID-19 | – | Other: Non applicable, is a patient registryMembranopathy-diagnosed patients (<18 years old) infected by COVID-19 |
| Adult Membranopathy patients infected by COVID-19 | – | Other: Non applicable, is a patient registryMembranopathy-diagnosed patients (<18 years old) infected by COVID-19 |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients both pediatric and adults with confirmed COVID19 and affected by a rare anaemia disorder due to a red blood cell defect according to the following ORPHA codes for rare diseases: * 68364 Hemoglobinopathy * 275752 Sickle Cell Disease and related diseases * 848 Beta-thalassemia * 846 Alpha-Thalassaemia * 98363 Rare hemolytic anemia * 98369 Rare constitutional hemolytic anemia due to an enzyme disorder * 98364 Rare constitutional hemolytic anemia due to a red cell membrane anomaly
Key inclusion criteria (1 listed)
- Patients both pediatric and adults with confirmed COVID-19 and affected by a rare anaemia disorder due to a red blood cell defect
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Non applicable, is a patient registryNon applicable, is a patient registry | Other | Adult Enzymopathy patients infected by COVID-19, Adult Membranopathy patients infected by COVID-19, Adult Sickle cell disease patients infected by COVID-19, Adult Thalassemia patients infected by COVID-19, Pediatric Enzymopathy patients infected by COVID-19, Pediatric Membranopathy patients infected by COVID-19, Pediatric Sickle cell disease patients infected by COVID-19, Pediatric Thalassemia patients infected by COVID-19 |
Primary outcome
Clinical Management and Outcomes in Patients with Red Blood Cell Disorders and COVID-19
Time frame: Through study completion, an average of 3 years
• COVID-19 clinical manifestations and required treatment in each cohort (Sickle Cell Disease, Thalassemia, Enzymopathies, and Membranopathies)..
1 secondary outcome
Secondary Analysis in Different Cohorts of Patients with Red Blood Cell Disorders and COVID-19:
Time frame: Through study completion, an average of 3 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Feb 2025.
- Registry platformLink provided by the sponsor.
- ERN-EuroBloodNet Collaborative Platform on Red Blood Cell and COVID-19 patients sectionLink provided by the sponsor.
- ERN-EuroBloodNet websiteLink provided by the sponsor.
- European Commission website section on European Reference NetworksLink provided by the sponsor.
- Directive 95/46/EC of the European Parliament and of the Council of 24 October 1995 on the protection of individuals with regard to the processing of personal data and on the free movement of such dataLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Hemoglobinopathies
Active, not recruitingPhase 1/2
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Long-term Mitapivat Dosing in Subjects With Stable Sickle Cell Disease: An Extension of a Phase I Pilot Study of Mitapivat
Sickle Cell Disease, Hemolytic Anemia
RecruitingObservational study
HPC Offered for PRESERVE Expansion
Bone Marrow Transplant (BMT)
RecruitingPhase 1
Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease
Sickle Cell Disorders, Sickle Cell Disease
RecruitingPhase 4
Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease
Sickle Cell Disease (SCD), Vaso-Occlusive Pain Episode in Sickle Cell Disease
Active, not recruiting
Evaluation the Safety and Efficacy of KL003 Cell Injection in the Treatment of Transfusion-dependent β-thalassemia.
Transfusion-dependent Beta-Thalassemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
María del Mar Mañú Pereira, PhD principal investigator
Vall d'Hebron Institut de Recerca, Barcelona (Spain) and ERN-EuroBloodNet
Pablo Velasco Puyó, MD principal investigator
Vall d'Hebron University Hospital, Barcelona (Spain)
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hemoglobinopathies and Sickle Cell Disease, run by Hospital Universitari Vall d'Hebron Research Institute at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Clinical Management and Outcomes in Patients with Red Blood Cell Disorders and COVID-19 (time frame: Through study completion, an average of 3 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Feb 2025.